Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Up 166.2% in April

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 19,071 shares, a growth of 166.2% from the April 15th total of 7,163 shares. Based on an average trading volume of 62,411 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the shares of the company are short sold.

Redhill Biopharma Stock Up 1.0%

Shares of RDHL stock traded up $0.01 during trading hours on Friday, hitting $1.03. 100,587 shares of the company’s stock were exchanged, compared to its average volume of 62,378. The firm has a market cap of $5.35 million, a P/E ratio of 0.00 and a beta of 5.05. The firm has a 50 day moving average of $0.89 and a two-hundred day moving average of $1.06. Redhill Biopharma has a fifty-two week low of $0.71 and a fifty-two week high of $3.31.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP bought a new position in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for approximately 0.3% of Yorkville Advisors Global LP’s holdings, making the stock its 19th biggest position. Yorkville Advisors Global LP owned approximately 7.57% of Redhill Biopharma as of its most recent SEC filing. Institutional investors own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Redhill Biopharma currently has an average rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.